William Sikov MD

Quick facts

Phase 2 pipeline

• Cohort 1 neo-adjuvant · Oncology
  This drug targets the PD-1 receptor to inhibit cancer cell growth.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• William Sikov MD portfolio CI brief
• William Sikov MD pipeline updates RSS